Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination tivozanib and nivolumab in for renal cell carcinoma (RCC) in the TiNivo-2 study ...
Please provide your email address to receive an email when new articles are posted on . The combination of amivantamab-vmjw and lazertinib extended OS by more than 1 year. Previously reported results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results